usamicro_0048|PHAS|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
usamicro_0048|PHAS|Long Name|1|1|PhaseBio Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Inventories (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Book Value (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc EV to Revenues|PhaseBio Pharmaceuticals Inc EV to Earnings|PhaseBio Pharmaceuticals Inc EV to Free Cash Flow|PhaseBio Pharmaceuticals Inc EV to Assets (Quarterly)|PhaseBio Pharmaceuticals Inc PS Ratio|PhaseBio Pharmaceuticals Inc PE Ratio|PhaseBio Pharmaceuticals Inc Price to Book Value|PhaseBio Pharmaceuticals Inc PEG Ratio|PhaseBio Pharmaceuticals Inc Debt to Equity Ratio|PhaseBio Pharmaceuticals Inc Dividend Yield|PhaseBio Pharmaceuticals Inc Shareholder Yield (TTM)|PhaseBio Pharmaceuticals Inc Percent of Shares Outstanding Short|PhaseBio Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Payables (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Return on Invested Capital|PhaseBio Pharmaceuticals Inc Quality Ratio Score|PhaseBio Pharmaceuticals Inc Momentum Score|PhaseBio Pharmaceuticals Inc Beta (1Y)|PhaseBio Pharmaceuticals Inc Sustainable Growth Rate (TTM)|PhaseBio Pharmaceuticals Inc Institutional Investor Ownership Percentage|PhaseBio Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|PhaseBio Pharmaceuticals Inc Total Employees (Annual)|PhaseBio Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Shares Outstanding|PhaseBio Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|PhaseBio Pharmaceuticals Inc Payout Ratio|PhaseBio Pharmaceuticals Inc Quick Ratio (Quarterly)|PhaseBio Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Effective Tax Rate (TTM)|PhaseBio Pharmaceuticals Inc Return on Equity|PhaseBio Pharmaceuticals Inc Net Income (TTM) (USD)|PhaseBio Pharmaceuticals Inc Revenue (TTM) (USD)|PhaseBio Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Revenue (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Price (USD)|PhaseBio Pharmaceuticals Inc Total Return Price (USD)|PhaseBio Pharmaceuticals Inc Enterprise Value (USD)|PhaseBio Pharmaceuticals Inc 30-Day Average Daily Volume|PhaseBio Pharmaceuticals Inc 1 Year Price Returns (Daily)
usamicro_0048|PHAS|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
usamicro_0048|PHAS||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily
usamicro_0048|PHAS||5|5|101.333333333|101.333333333|0|101.333333333|0|101.333333333|101.333333333|101.333333333|0|101.333333333|101.333333333|101.333333333|1.44011976048|91.5|1.43913043478|91.1666666667|1.44011976048|0|1.43913043478|0|91.3333333333|1.45078740157|91.6666666667|15.2173913043|101.333333333|101.333333333|101.333333333|91.6666666667|0|30.5|30.4545454545|91.6666666667|30.5|91.2727272727|114|91.2727272727|35.3157894737|0|101.333333333|91.6666666667|91.3333333333|91.2727272727|91.375|0|91.6666666667|91.375|91.6666666667|0|91.3333333333|0|91.2727272727|91.2727272727|91.2727272727|91.2727272727|1.45078740157|1.45078740157|1.44509803922|1.4509394572|1.44747081712
usamicro_0048|PHAS||6|6|9|9|0|9|0|9|9|9|0|9|9|9|334|4|460|6|334|0|460|0|6|508|3|46|9|9|9|3|0|10|11|3|14|11|8|11|19|0|9|3|6|11|8|0|3|8|3|0|6|0|11|11|11|11|508|508|510|479|257
usamicro_0048|PHAS||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
usamicro_0048|PHAS|201709|201709|201709||||||||||||||||||||||||||||||||||12.3923||-0.2066||||||-0.2017|||||||||0.565|-2.56|-2.56|-0.604|||||
usamicro_0048|PHAS|201712|201712|201712|13.766|13.406||0.302||111.515|17.595|93.92||-97.416|-99.065|0.024|||||||||||||0|0.43|0.001|||||||12.3923|18|-0.2046|||19.5884|||-0.2861|||||||||0.628|-2.535|-2.535|-1.095|||||
usamicro_0048|PHAS|201803|201803|201803||||||||||||||||||||||||||||||||||12.3923||-0.3553||||||-0.3426|||||||||0.643|-4.403|-4.403|-1.368|||||
usamicro_0048|PHAS|201806|201806|201806|28.664|28.446||0.276||9.247|5.117|4.13||20.354|-110.142|0.024||||||||||||||0.569|0.015|||||||19.5884||-0.3407|||19.5884|||-0.2817|0|||-16.172|||||0.917|-6.674|-6.674|-1.411|||||
usamicro_0048|PHAS|201809|201809|201809|24.968|24.341||0.251||143.662|7.688|135.974||-116.174|-118.043|0.024|||||||||-0.0646||||0.411|1.576|0.001|||||||19.5884|19|-0.4034|||19.5884||3.2196|-0.2976|0|||-21.513|||0.411||1.056|-7.901|-7.901|-0.83|||||
usamicro_0048|PHAS|201810|201809|201809||||||||||||||||||||||0||0.0171|||||||||||||23.8038||||||||||||||||||5.1|5.1|104.5584||
usamicro_0048|PHAS|201811|201809|201809||||||||||||||||||||||0||0.1132|||||||||||||24.4983||||||||||||||||||2.85|2.85|52.9792|69780.2667|
usamicro_0048|PHAS|201812|201812|201812|62.628|61.031||0.355||12.099|4.577|7.522||50.927|-122.911|0.024|||-1.291|0.3517|||1.4864||0.1473|0||0.163|0.233|1.806|0.025|||||||24.4983|24|-0.26|24.4983||24.4983||13.3852|-0.371|-42.974|||-23.846|||0.257||2.241|-4.868|-4.868|0.072|3.09|3.09|22.1687|50348.0333|
usamicro_0048|PHAS|201901|201812|201812|||||||||||||||-1.5906||||1.5875|||0||0.0808|||||||||||||||||||||||||||||||3.3|3.3|27.3134|34638.7|
usamicro_0048|PHAS|201902|201812|201812|||||||||||||||-1.3893||||1.5196|||0||0.0479|||||||||||||||||||||||||||||||3.1589|3.1589|23.8567|16632.2333|
usamicro_0048|PHAS|201903|201903|201903|54.075|51.894||2.279||12.304|3.797|8.507||44.082|-130.204|0.024|||-8.0674|3.3404|||||0.1648|0||0.5959|0.67|2.058|0.025|||||||24.4984|27|-0.3|24.4984||24.4984||13.8436|-0.3||||-26.736|||0.653||2.316|-7.293|-7.293|0.091|9.51|9.51|188.3498|343368.5333|
usamicro_0048|PHAS|201904|201903|201903|||||||||||||||-14.1487||||8.506|||0||2.2099|||||||||||||28.6229||||||||||||||||||13.1|13.1|330.33|719307.5667|
usamicro_0048|PHAS|201905|201903|201903|||||||||||||||-11.1837||||6.9356|||0||1.6848|||||||||||||28.627||||||||||||||||||10.68|10.68|261.1064|201803.2333|
usamicro_0048|PHAS|201906|201906|201906|94.897|90.342||2.509||15.829|5.746|10.083||81.609|-139.436|0.024|146.1781|-10.0998|-9.9287|3.0364|156.412||||0.1188|0|-23.8638|1.9965|1.18|3.047|0.029|-126.8111||||-181.2792||27.9326|30|-0.33|28.6976||28.6976|0|15.928|-0.3292|-46.308||-181.2792|-29.294|2.024||0.703||2.404|-9.232|-9.232|0.272|13.12|13.12|295.8645|205671.3667|
usamicro_0048|PHAS|201907|201906|201906|||||||||||||70.8895||-4.8149||93.1081||2.7464|||0||3.1664|||||||||92.7001||||||||||||||||||||||7.81|7.81|143.4803|196092.8|
usamicro_0048|PHAS|201908|201906|201906|||||||||||||82.6629||-5.6146||103.0031||3.0384|||0||3.7295|||||||||93.0579||||28.6988||||||||||||||||||8.64|8.64|167.3096|115936.9|
usamicro_0048|PHAS|201909|201909|201909|83.369|81.771||2.802||15.399|5.962|9.437||70.804|-150.827|0.024|25.8135|-1.4598|-1.3731|0.5552|59.4063||1.6934||0.1374|0|-74.7287|6.1067|0.583|1.659|0.029|-94.7865||||-124.8933|93.8506|28.7199|32|-0.4|28.7528||28.7528|0|13.8132|-0.4005|0.031||-124.8933|-32.784|1.854||0.241||2.803|-11.391|-11.391|0.185|4.17|4.17|47.8582|516493.3333|
usamicro_0048|PHAS|201910|201909|201909|||||||||||||24.883||-1.3236||58.5515||1.669|||0||5.9324|||||||1.3782||93.428||||||||||||||||||||||4.11|4.11|46.133|519472.6667|-19.4118
usamicro_0048|PHAS|201911|201909|201909|||||||||||||11.7245||-0.6236||46.4423||1.3245|||0||6.7368||||||4|1.2271||94.7021||||28.7663||||||||||||||||||3.26|3.26|21.7371|215143.1667|12.8028
usamicro_0048|PHAS|201912|201912|201912|78.823|74.025||3.639||22.516|8.479|14.037||59.978|-162.158|0.024|49.3188|-2.9669|-2.8713|1.4115|71.1202||2.9305||0.2452|0|-27.149|7.9501|1.233|2.921|0.029|-55.077||7|2.1834|-63.837||28.7769|40|-0.39|28.7664||28.7664|0|8.8758|-0.3897|0||-63.837|-39.247|2.361||0.764||3.663|-11.331|-11.331|-0.042|6.11|6.11|116.4417|576613.2|97.7346
usamicro_0048|PHAS|202001|201912|201912|||||||||||||35.5509||-2.0697||57.967||2.3885|||0||9.8667||||||10|3.9354||91.407||||||||||||||||||||||4.98|4.98|83.9357|860415.4333|50.9091
usamicro_0048|PHAS|202002|201912|201912|||||||||||||26.1692||-1.5235||49.0043||2.0192|||0||9.857||||||9|3.973||91.4736||||||||||||||||||||||4.21|4.21|61.7855|294156.8333|33.2742
usamicro_0048|PHAS|202003|202003|202003|72.541|59.441||4.285||23.372|7.495|15.877||53.486|-177.063|0.024|24.9343|-1.0791|-0.8994|0.6579|46.599||1.7811||0.2757|0|-50.0986|9.612|0.896|1.918|0.029|-63.9984||9|2.2926|-75.589|82.6816|28.7733|40|-0.52|28.7806||28.7806|0|8.0503|-0.5044|||-75.589|-46.859|2.028||0.32||3.159|-14.905|-14.905|-0.167|3.31|3.31|50.5668|304164.2|-65.1945
usamicro_0048|PHAS|202004|202003|202003|||||||||||||32.7397||-1.1809||54.342||2.077|||0||8.4094||||||2|1.7921||76.9532||||28.7806||||||||||||||||||3.86|3.86|66.3961|243141.6667|-70.5344
usamicro_0048|PHAS|202005|202003|202003|||||||||||||63.2529||-2.2815||84.6103||3.234|||0||6.8813||||||2|2.143||76.903||||28.781||||||||||||||||||6.01|6.01|128.2768|1097630.2667|-47.9203
usamicro_0048|PHAS|202006|202006|202006|63.741|53.025||7.012||44.417|17.802|26.615||26.393|-205.205|0.024|46.6082|-2.0171|-1.7116|1.2298|65.2548||5.0302|||0||10.8621|0|6.967|0.029|||3|1.9495||74.9851|28.8052|50|-0.98|28.8616||28.8616|||-0.852|-0.472|||-65.769|||||3.242|-28.142|-28.142|-0.358|4.6|4.6|94.5214|1221574.7333|-64.939
usamicro_0048|PHAS|202007|202006|202006|||||||||||||38.0692||-1.398||56.7433||4.3741|||0||12.7425||||||2|1.774||74.3328||||||||||||||||||||||4|4|77.2044|521499.4|-48.7836
usamicro_0048|PHAS|202008|202006|202006|||||||||||||36.9929||-1.3585||54.7573||4.2914|||0||12.6855||||||2|1.7209||73.0666||||29.3429||||||||||||||||||3.86|3.86|75.0216|471659.7333|-55.3241
usamicro_0048|PHAS|202009|202009|202009|||||||||||||31.9288||-1.1725||49.7922||3.9023|||0||13.0393||||||2|1.7528||73.0707||||||||||||||||||||||3.51|3.51|64.7516|247177.4333|-15.8273
usamicro_0048|PHAS|202010|202009|202009|||||||||||||25.9242||-0.952||43.9051||3.4409|||0|||||||||||||||||||||||||||||||||3.095|3.095|52.5743|157444.8667|-25.0605